We See What We Treat: Radiopharmaceutical's Explained

So the other piece that you think about in this category is get into your job, but get out.

Yeah.

What's that all about? Where does it go? And is it something that's a better way to approach things than other therapies? Think of chemotherapy by its very nature.

It's the poisoning what's doing its job and hopefully the healthy tissue regenerates.

So this could be quicker.

And

that's yet another problem.

Major area of our ongoing discussions at all of our society meetings, at the scientific publication presentations.

As you mentioned, there are so many different targets that are designed.

So imagine if there is one target that goes in and out of the cell.

If you then combine it with a half-life that is much longer, the patient is getting unnecessary radiation to the rest of the body.

We are so grateful to our very smart radiochemists who are constantly thinking of this.

So what they do is that they design these molecules, which have been very much right from the ground up, purposefully thought out.

So if you have a small molecule that goes in and out of the body quickly, then you want to combine it with the isotope that has a shorter half-life so that it goes in and out and that you can now avoid some normal organs from getting unnecessary toxicity.

On the other hand, if something that stays to the cancer cells for a longer time, then you want to design with the longer half-life agents.

And it's even getting even more sophisticated to a point where you mentioned about ADCs

earlier.

There are several trials where we can have a chemotherapy being delivered to the specific cancer cells through the carrier, but now they're tagging along a radioisotope with it as well.

And those could be designed in a way that if that cancer cell is holding on to that molecule, then you give a longer half-life agent that preferentially just sits in the cancer cells and washes out the rest of the body so the normal organs don't get much exposure.

I mean, sky is the limit, the way combining different size of the molecules, different half-life, using other technologies such as ADCs and nanotechnology, even pre-target.

So the other option is where these are targeted without the radioactive isotope, just the antibody first.

Let the antibody wash out.

And now you have another one I still administered later than it just targets only to those areas where antibodies have been deposited.

I can see for the next five to 10 years is going to be some real amazing new developments in the radiopharmaceutical therapies.